When we have the opportunity to talk to the dedicated and talented people in the cancer research community, one thing is clear - The Cure is a question of time and money. Cancer is a complex foe, and increasingly it is the belief that treatment and eradication will be based on individual combinations of genetic markers.
Since inception, we've focused our donations on proof of concept research that, if successful, will lead to larger grants for cutting edge, collaborative research at some of our Nation's finest institutions. There is a dearth of funding in this area. When a talented researcher has a theory, they often need to conduct a small study showing promise to procure funding from larger research institutions like National Institutes of Health (NIH) or National Cancer Institute (NCI) . This could mean they need a research assistant, investigative equipment or the like - in this case, tens of thousands of dollars can make all the difference and lead to millions of research dollars for that research. This is where we put our money. Our recipients estimate that they receive a 6-12x multiple in the form of larger grants from these monies.
To date, we've funded researchers at the Lombardi Cancer Center, Johns Hopkins University, INNOVA Health Centers, Duke University, and the University of Virginia Cancer Center
If you have questions about where Swing Fore the Cure donation dollars are being spent, we would love to hear from you. See our contact information.
RECENT RESEARCH NEWS...
Swing is credited for funding support in this recent publication: Pioneering Research Illuminates Breast Cancer, Like You've Never Seen it Before
DEB LANIGAN, Ph.D.
Part of our dollars have gone to fund Deb Lanigan's work - Deb is a cellular biologist who has discovered a new drug (SL0101) which shows significant promise and is moving to larger scale testing in mice now. This is an incredible development as most new drug discovery in recent history was made by large pharmaceudical companies. See more here.
In addition, Dr. Lanigan's colleague Karin Eisinger-Mathason recently published in the prestigious Molecular Cell journal based on research we funded (Swing actually shows up in the acknowledgements). See more here.